ClinicalTrials.gg
RecruitingNCT07078136Updated Jul 31, 2025

Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis

An observational study in Submucosal Tumor, Gastrointestinal Stromal Tumor (GIST) and Leiomyoma, sponsored by Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Gastrointestinal Stromal Tumors with a site in China — 24 open to participants now, 28 under way, 4 of them phase 3. Gastrointestinal Stromal Tumors · China.

Planned enrollment
13th of 22
130 · median 181
Started
2025
with 7 others
Observational
22 of 69
8 open now
Primary completion
2026-03
later than 8 of 27 live
Registered
59th of 69
by date
Lead sponsor
3 of 69
Huazhong University of Science and Technology

Among the 69 studies in Gastrointestinal Stromal Tumors with a site in China, this one is the 13th largest by planned enrollment of the 22 observational ones that give a count, is one of 8 that started in 2025, is one of 22 observational ones, reaches primary completion later than 8 of the 27 other live ones, and was the 59th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

24 of the 69 studies in Gastrointestinal Stromal Tumors with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Gastrointestinal Stromal Tumors with a site in China, or all of them as a file.
02

Study summary

This study develops a multimodal AI model using endoscopic ultrasound, white-light endoscopy, and clinical information to support the diagnosis of upper GI mesenchymal tumors and the risk stratification of gastric GISTs.

Read the detailed description

This is a multicenter, observational study designed to evaluate the diagnostic performance of a multimodal artificial intelligence (AI) model for the classification of upper gastrointestinal subepithelial lesions (SELs) and risk stratification of gastric gastrointestinal stromal tumors (gGISTs). The study combines retrospective image data for training and validation with prospectively recruited cases for testing.

Endoscopic ultrasound (EUS) images, white-light endoscopy (WLE) images, and relevant clinical data will be collected according to strict image quality control criteria. The multimodal AI model integrates these inputs using a multi-branch fusion strategy. A cross-validation trial will be conducted using prospectively recruited patients' data from multiple centers to compare the diagnostic and predictive performance of endoscopists with and without AI assistance for both lesion classification and risk stratification.

According to existing literature, no multimodal AI model has yet reported diagnostic performance for classifying SELs or for risk stratification of gastric gGISTs. It is assumed that the multimodal AI model will achieve a diagnostic accuracy of 95% for classifying upper gastrointestinal SELs and 95% for gGIST risk stratification. In comparison, the diagnostic accuracy of endoscopists is approximately 73.3%-75% for differentiating GIST from non-GIST and 72.4%-78.9% for risk stratification of gGISTs . GISTs account for about 67-68% of all lesions . Using a two-sided confidence interval with α = 0.05 and β = 0.2, and considering a 20% potential dropout rate, the minimum sample size required for prospective SEL classification is 65 cases, and 88 gGIST cases for risk stratification. Since the risk stratification task requires a larger sample size and GISTs are the common target of both tasks, the final planned sample size is 130 patients with upper GI SELs, which meets the statistical requirements for all primary endpoints.

The study team will screen patients based on the inclusion and exclusion criteria, ensure that all required examinations are completed to confirm eligibility, and record pre-treatment test results. All prospective participants will provide written informed consent before any study-related examinations.

This study is purely observational. No additional interventions will be performed on participants, nor will any additional costs be incurred. Patients' access to optimal diagnostic or treatment options will not be affected. The primary potential risk is the breach of patient privacy; the research team will establish a strict data security and monitoring plan and inform participants that their data will be used for clinical research purposes.

This study is purely observational. No additional interventions will be performed on participants, nor will any additional costs be incurred. Patients' access to optimal diagnostic or treatment options will not be affected. The primary potential risk is the breach of patient privacy; the research team will establish a strict data security and monitoring plan and inform participants that their data will be used for clinical research purposes.

Each enrolled participant will undergo diagnostic assessment by both the multimodal AI model and expert endoscopists. The AI model and expert interpretation will be blinded to each other. Final diagnosis will be confirmed by histopathology. Diagnostic performance will be compared using paired analysis. All statistical tests will be two-sided, and differences will be considered statistically significant at P \< 0.05. Continuous variables will be described as mean ± standard deviation. Categorical variables will be presented as counts and percentages. (1) Diagnostic Performance: The diagnostic performance of endoscopists and the AI model will be compared using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the curve (AUC). F1-score (harmonic mean) and balanced accuracy will be calculated to address class imbalance (e.g., GIST vs. other lesions). (2) Continuous Data: Comparisons with baseline values will be conducted using paired t-tests, ANOVA, or rank-sum tests as appropriate. (3) Categorical Data: Group comparisons will use Chi-square tests (including CMH Chi-square test) or Fisher's exact test. (4) Baseline Comparability: Demographic and baseline characteristics will be compared using independent t-tests or Chi-square tests to assess group balance. (5) Effectiveness Analysis: The primary effectiveness endpoint is the diagnostic accuracy for GI subepithelial lesions. The difference in proportions and Youden index will be compared using the approximate normal Z test or Chi-square test with center effect control. (6) Software: All statistical analyses will be performed using SPSS version 26.0.

03

Conditions studied

  • Submucosal Tumor
  • Gastrointestinal Stromal Tumor (GIST)
  • Leiomyoma
  • Schwannoma

Keywords

  • Artificial Intelligence
  • Endoscopic ultrasound
  • white-light endoscopy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The cohort will be selected from several hospitals in China, including Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patients with an upper gastrointestinal subepithelial lesion (SEL) identified by white-light endoscopy and who have completed an endoscopic ultrasound (EUS) examination
  • Patients with a histopathological diagnosis of GIST confirmed by surgical or endoscopic resection, or other SELs confirmed by surgical resection, EUS-guided sampling, or other techniques
  • EUS image quality meets the following quality control standards

    1. Equipment requirements: Olympus EU-ME2/ME1 processor (Olympus Medical Systems Corp., Tokyo, Japan); radial EUS scope (GF-UE260/GF-UE240; Olympus, Tokyo, Japan) or linear EUS scope (GF-UCT260/GF-UCT240; Olympus, Tokyo, Japan); miniature probe (UM2R/3R; Olympus, Tokyo, Japan); Pentax ARIETTA 850 processor (Pentax, Tokyo, Japan); radial EUS scope (EG-3670URK, Pentax, Tokyo, Japan); linear EUS scope (EG-3870UT, Pentax, Tokyo, Japan); Fujifilm SU-8000 or SU-9000 processor; linear EUS scope (EG-580UT, Fujifilm, Tokyo, Japan); radial EUS scope (EG-580UR, Fujifilm, Tokyo, Japan)
    2. EUS images clearly showing the lesion and surrounding tissue characteristics (at least 5 images or video); must include at least one image of the maximum lesion diameter, one image showing the layer of origin, and one image demonstrating the growth pattern (intraluminal/extraluminal)
    3. EUS images must not contain artificial annotations, such as measurement scales, biopsy needles, Doppler signals, or elastography overlays
    4. Image resolution must be at least 448 × 448 pixels
  • WLE (white-light endoscopy) image quality meets the following standards: images must clearly show the lesion location, mucosal features, and margins; at least one close-up and one distant view
  • Complete clinical data and histopathological reports must be available

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old
  • Absolute for EUS examination, history of gastric surgery, pregnancy, severe comorbidities, or known allergy to anesthetic agents
  • EUS examination terminated prematurely due to esophageal stricture, obstruction, large space-occupying lesions, rapid changes in heart rate or respiratory rate, patient intolerance, or excessive residual food
  • EUS image quality does not meet the required quality control standards
  • Pathological specimens do not meet diagnostic requirements: insufficient tissue (only R0 resection specimens are accepted for the GIST group), or incomplete immunohistochemical staining (missing CD117/CD34/DOG-1 expression report for the GIST group)
  • Pathological results indicate that the lesion is a tumor originating from another site
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Groups and cohorts

  • All Participants

    All enrolled patients with upper gastrointestinal subepithelial lesions confirmed by histopathology. Each participant will undergo standard diagnostic evaluation and independent multimodal AI prediction and expert endoscopist diagnosis.

    Diagnostic Test: Multimodal AI Model · Diagnostic Test: Expert Endoscopist Assessment

Interventions

  • Diagnostic testMultimodal AI Model

    Patients' endoscopic images, EUS images, and clinical data will be analyzed by a multimodal AI model for lesion classification and GIST risk stratification.

  • Diagnostic testExpert Endoscopist Assessment

    Endoscopic ultrasound images will be interpreted by experienced endoscopists for comparison with the AI model.

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of a multimodal AI model for differentiating gastrointestinal stromal tumors (GISTs) from other upper gastrointestinal mesenchymal tumors

    Receiver operating characteristic (ROC) analyses, sensitivity, specificity, accuracy, positive predictive value and negative predictive value will be used to evaluate the efficacy of the model

    Time frame: After the training process of the multimodal AI model is completed,on average per year

  2. Predictive accuracy of the multimodal AI model for risk stratification of GISTs

    ROC analyses, sensitivity, specificity, accuracy, positive predictive value and negative predictive value will be used to evaluate the efficacy of the model

    Time frame: After the training process of the multimodal AI model is completed,on average per year

Secondary outcomes

  1. Comparison of Diagnostic Accuracy Between the Multimodal AI Model and Single-Modality Models

    Receiver operating characteristic (ROC) analyses, sensitivity, specificity, accuracy, positive predictive value and negative predictive value will be used to evaluate the efficacy of the model

    Time frame: After the training process of the Multimodal AI model is completed,on average per year

  2. Comparison of diagnostic accuracy between the multimodal AI model and experienced endoscopists for differentiating GISTs and non-GIST mesenchymal tumors

    The diagnostic accuracy of the AI model and expert endoscopists will be compared within the same participants, using histopathology as the gold standard. Receiver operating characteristic (ROC) analyses, sensitivity, specificity, accuracy, positive predictive value and negative predictive value will be used to evaluate the efficacy of the model

    Time frame: After the testing process of the multimodal AI model is completed,on average per year

  3. Comparison of the predictive accuracy for GIST risk stratification between the multimodal AI model and experienced endoscopists

    The diagnostic accuracy of the AI model and expert endoscopists will be compared within the same participants, using histopathology as the gold standard. Receiver operating characteristic (ROC) analyses, sensitivity, specificity, accuracy, positive predictive value and negative predictive value will be used to evaluate the efficacy of the model

    Time frame: After the testing process of the multimodal AI model is completed,on average per year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chinese Society of Digestive Endoscopy Tunnel Technology Collaboration Group, Endoscopist Branch of Chinese Medical Doctor Association, and Digestive Endoscopy Branch of Beijing Medical Association. Expert Consensus on Endoscopic Diagnosis and Treatment of Gastrointestinal Stromal Tumors in China (2020, Beijing). Chinese Journal of Digestive Endoscopy, 2021(07): 505-514.
  • Shen L, Cao H, Qin S, et al. Chinese Consensus on the Diagnosis and Treatment of Gastrointestinal Stromal Tumors (2017 Version). Electronic Journal of Integrated Cancer Therapy, 2018; 4(01): 31-43.
  • Gomes RSA, de Oliveira GHP, de Moura DTH, Kotinda APST, Matsubayashi CO, Hirsch BS, Veras MO, Ribeiro Jordao Sasso JG, Trasolini RP, Bernardo WM, de Moura EGH. Endoscopic ultrasound artificial intelligence-assisted for prediction of gastrointestinal stromal tumors diagnosis: A systematic review and meta-analysis. World J Gastrointest Endosc. 2023 Aug 16;15(8):528-539. doi: 10.4253/wjge.v15.i8.528. PubMed 37663113 ↗
  • Abe K, Tominaga K, Yamamiya A, Inaba Y, Kanamori A, Kondo M, Suzuki T, Watanabe H, Kawano M, Sato T, Yoshitake N, Ohwada T, Konno M, Hanatsuka K, Masuyama H, Goda K, Haruyama Y, Irisawa A; NUTSHELL20 Study group. Natural History of Small Gastric Subepithelial Lesions Less than 20 mm: A Multicenter Retrospective Observational Study (NUTSHELL20 Study). Digestion. 2023;104(3):174-186. doi: 10.1159/000527421. Epub 2022 Dec 5. PubMed 36470211 ↗
  • Standards of Practice Committee; Faulx AL, Kothari S, Acosta RD, Agrawal D, Bruining DH, Chandrasekhara V, Eloubeidi MA, Fanelli RD, Gurudu SR, Khashab MA, Lightdale JR, Muthusamy VR, Shaukat A, Qumseya BJ, Wang A, Wani SB, Yang J, DeWitt JM. The role of endoscopy in subepithelial lesions of the GI tract. Gastrointest Endosc. 2017 Jun;85(6):1117-1132. doi: 10.1016/j.gie.2017.02.022. Epub 2017 Apr 3. No abstract available. PubMed 28385194 ↗
  • Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y, He Y, Liang X, Liu X, Zhou Y, Wu X, Zhang X, Wang M, Gao Z, Lin T, Cao H, Shen L, Chinese Society Of Clinical Oncology Csco Expert Committee On Gastrointestinal Stromal Tumor. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017 Aug;29(4):281-293. doi: 10.21147/j.issn.1000-9604.2017.04.01. PubMed 28947860 ↗
  • Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005 Jan;29(1):52-68. doi: 10.1097/01.pas.0000146010.92933.de. PubMed 15613856 ↗
  • Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, Hosoya Y, Nakajima T, Funata N. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006 Dec;37(12):1527-35. doi: 10.1016/j.humpath.2006.07.002. Epub 2006 Sep 25. PubMed 16996566 ↗
  • Pang T, Zhao Y, Fan T, Hu Q, Raymond D, Cao S, Zhang W, Wang Y, Zhang B, Lv Y, Zhang X, Ling T, Zhuge Y, Wang L, Zou X, Huang Q, Xu G. Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Small (</= 5 cm) Primary Gastric Gastrointestinal Stromal Tumors. J Cancer. 2019 Jul 10;10(17):4132-4141. doi: 10.7150/jca.29443. eCollection 2019. PubMed 31417658 ↗
  • Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, Sicklick JK. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. J Gastrointest Surg. 2016 Jun;20(6):1132-40. doi: 10.1007/s11605-016-3134-y. Epub 2016 Mar 29. PubMed 27025710 ↗
  • Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016 Jan;19(1):3-14. doi: 10.1007/s10120-015-0526-8. Epub 2015 Aug 15. PubMed 26276366 ↗
  • Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Alava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krakorova DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schoffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv267. doi: 10.1093/annonc/mdy320. No abstract available. PubMed 30188977 ↗
  • von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Koon H, Mayerson J, McCarter M, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Petersen IA, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Tap WD, Wayne JD, Bergman MA, Scavone J. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Jun;14(6):758-86. doi: 10.6004/jnccn.2016.0078. PubMed 27283169 ↗
  • Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, Otani Y, Shimada Y, Takahashi F, Kubota T; GIST Guideline Subcommittee. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008 Oct;13(5):416-30. doi: 10.1007/s10147-008-0798-7. Epub 2008 Oct 23. PubMed 18946752 ↗
  • Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Alava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krakorova DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schoffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21. No abstract available. PubMed 34560242 ↗
  • Baysal B, Masri OA, Eloubeidi MA, Senturk H. The role of EUS and EUS-guided FNA in the management of subepithelial lesions of the esophagus: A large, single-center experience. Endosc Ultrasound. 2017 Sep-Oct;6(5):308-316. doi: 10.4103/2303-9027.155772. PubMed 26365993 ↗
  • Daimaru Y, Kido H, Hashimoto H, Enjoji M. Benign schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. Hum Pathol. 1988 Mar;19(3):257-64. doi: 10.1016/s0046-8177(88)80518-5. PubMed 3126126 ↗
  • Mekras A, Krenn V, Perrakis A, Croner RS, Kalles V, Atamer C, Grutzmann R, Vassos N. Gastrointestinal schwannomas: a rare but important differential diagnosis of mesenchymal tumors of gastrointestinal tract. BMC Surg. 2018 Jul 25;18(1):47. doi: 10.1186/s12893-018-0379-2. PubMed 30045739 ↗
  • Lauricella S, Valeri S, Masciana G, Gallo IF, Mazzotta E, Pagnoni C, Costanza S, Falcone L, Benvenuto D, Caricato M, Capolupo GT. What About Gastric Schwannoma? A Review Article. J Gastrointest Cancer. 2021 Mar;52(1):57-67. doi: 10.1007/s12029-020-00456-2. PubMed 32964322 ↗
  • Karaca C, Turner BG, Cizginer S, Forcione D, Brugge W. Accuracy of EUS in the evaluation of small gastric subepithelial lesions. Gastrointest Endosc. 2010 Apr;71(4):722-7. doi: 10.1016/j.gie.2009.10.019. Epub 2010 Feb 19. PubMed 20171632 ↗
  • Hwang JH, Saunders MD, Rulyak SJ, Shaw S, Nietsch H, Kimmey MB. A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses. Gastrointest Endosc. 2005 Aug;62(2):202-8. doi: 10.1016/s0016-5107(05)01567-1. PubMed 16046979 ↗
  • Minoda Y, Chinen T, Osoegawa T, Itaba S, Haraguchi K, Akiho H, Aso A, Sumida Y, Komori K, Ogino H, Ihara E, Ogawa Y. Superiority of mucosal incision-assisted biopsy over ultrasound-guided fine needle aspiration biopsy in diagnosing small gastric subepithelial lesions: a propensity score matching analysis. BMC Gastroenterol. 2020 Jan 21;20(1):19. doi: 10.1186/s12876-020-1170-2. PubMed 31964357 ↗
  • de Moura DTH, McCarty TR, Jirapinyo P, Ribeiro IB, Flumignan VK, Najdawai F, Ryou M, Lee LS, Thompson CC. EUS-guided fine-needle biopsy sampling versus FNA in the diagnosis of subepithelial lesions: a large multicenter study. Gastrointest Endosc. 2020 Jul;92(1):108-119.e3. doi: 10.1016/j.gie.2020.02.021. Epub 2020 Feb 25. PubMed 32105712 ↗
  • Osoegawa T, Minoda Y, Ihara E, Komori K, Aso A, Goto A, Itaba S, Ogino H, Nakamura K, Harada N, Makihara K, Tsuruta S, Yamamoto H, Ogawa Y. Mucosal incision-assisted biopsy versus endoscopic ultrasound-guided fine-needle aspiration with a rapid on-site evaluation for gastric subepithelial lesions: A randomized cross-over study. Dig Endosc. 2019 Jul;31(4):413-421. doi: 10.1111/den.13367. Epub 2019 Apr 2. PubMed 30723945 ↗
  • Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008 Oct;39(10):1411-9. doi: 10.1016/j.humpath.2008.06.025. PubMed 18774375 ↗
  • Shah P, Gao F, Edmundowicz SA, Azar RR, Early DS. Predicting malignant potential of gastrointestinal stromal tumors using endoscopic ultrasound. Dig Dis Sci. 2009 Jun;54(6):1265-9. doi: 10.1007/s10620-008-0484-7. Epub 2008 Aug 29. PubMed 18758957 ↗
  • Chen T, Xu L, Dong X, Li Y, Yu J, Xiong W, Li G. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm. Eur Radiol. 2019 May;29(5):2481-2489. doi: 10.1007/s00330-018-5945-6. Epub 2019 Jan 7. PubMed 30617491 ↗
  • Chen H, Xu Z, Huo J, Liu D. Submucosal tunneling endoscopic resection for simultaneous esophageal and cardia submucosal tumors originating from the muscularis propria layer (with video). Dig Endosc. 2015 Jan;27(1):155-8. doi: 10.1111/den.12227. Epub 2014 Jan 20. PubMed 24444087 ↗
  • He G, Wang J, Chen B, Xing X, Wang J, Chen J, He Y, Cui Y, Chen M. Feasibility of endoscopic submucosal dissection for upper gastrointestinal submucosal tumors treatment and value of endoscopic ultrasonography in pre-operation assess and post-operation follow-up: a prospective study of 224 cases in a single medical center. Surg Endosc. 2016 Oct;30(10):4206-13. doi: 10.1007/s00464-015-4729-1. Epub 2016 Jan 28. PubMed 26823060 ↗
  • Hirai K, Kuwahara T, Furukawa K, Kakushima N, Furune S, Yamamoto H, Marukawa T, Asai H, Matsui K, Sasaki Y, Sakai D, Yamada K, Nishikawa T, Hayashi D, Obayashi T, Komiyama T, Ishikawa E, Sawada T, Maeda K, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Kawashima H, Ishigami M, Fujishiro M. Artificial intelligence-based diagnosis of upper gastrointestinal subepithelial lesions on endoscopic ultrasonography images. Gastric Cancer. 2022 Mar;25(2):382-391. doi: 10.1007/s10120-021-01261-x. Epub 2021 Nov 16. PubMed 34783924 ↗
  • Byrne MF, Chapados N, Soudan F, Oertel C, Linares Perez M, Kelly R, Iqbal N, Chandelier F, Rex DK. Real-time differentiation of adenomatous and hyperplastic diminutive colorectal polyps during analysis of unaltered videos of standard colonoscopy using a deep learning model. Gut. 2019 Jan;68(1):94-100. doi: 10.1136/gutjnl-2017-314547. Epub 2017 Oct 24. PubMed 29066576 ↗
  • Yang X, Wang H, Dong Q, Xu Y, Liu H, Ma X, Yan J, Li Q, Yang C, Li X. An artificial intelligence system for distinguishing between gastrointestinal stromal tumors and leiomyomas using endoscopic ultrasonography. Endoscopy. 2022 Mar;54(3):251-261. doi: 10.1055/a-1476-8931. Epub 2022 Jun 9. PubMed 33827140 ↗
  • Oh CK, Kim T, Cho YK, Cheung DY, Lee BI, Cho YS, Kim JI, Choi MG, Lee HH, Lee S. Convolutional neural network-based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images. J Gastroenterol Hepatol. 2021 Dec;36(12):3387-3394. doi: 10.1111/jgh.15653. Epub 2021 Aug 16. PubMed 34369001 ↗
  • Niikura R, Aoki T, Shichijo S, Yamada A, Kawahara T, Kato Y, Hirata Y, Hayakawa Y, Suzuki N, Ochi M, Hirasawa T, Tada T, Kawai T, Koike K. Artificial intelligence versus expert endoscopists for diagnosis of gastric cancer in patients who have undergone upper gastrointestinal endoscopy. Endoscopy. 2022 Aug;54(8):780-784. doi: 10.1055/a-1660-6500. Epub 2022 May 4. PubMed 34607377 ↗
  • Liu J, Huang J, Song Y, He Q, Fang W, Wang T, Zheng Z, Liu W. Differentiating Gastrointestinal Stromal Tumors From Leiomyomas of Upper Digestive Tract Using Convolutional Neural Network Model by Endoscopic Ultrasonography. J Clin Gastroenterol. 2024 Jul 1;58(6):574-579. doi: 10.1097/MCG.0000000000001907. PubMed 37646533 ↗
  • Lu Y, Chen L, Wu J, Er L, Shi H, Cheng W, Chen K, Liu Y, Qiu B, Xu Q, Feng Y, Tang N, Wan F, Sun J, Zhi M. Artificial intelligence in endoscopic ultrasonography: risk stratification of gastric gastrointestinal stromal tumors. Ther Adv Gastroenterol. 2023 May 30;16:17562848231177156. doi: 10.1177/17562848231177156. eCollection 2023. PubMed 37274299 ↗
  • Seven G, Silahtaroglu G, Kochan K, Ince AT, Arici DS, Senturk H. Use of Artificial Intelligence in the Prediction of Malignant Potential of Gastric Gastrointestinal Stromal Tumors. Dig Dis Sci. 2022 Jan;67(1):273-281. doi: 10.1007/s10620-021-06830-9. Epub 2021 Feb 6. PubMed 33547537 ↗
  • Kline A, Wang H, Li Y, Dennis S, Hutch M, Xu Z, Wang F, Cheng F, Luo Y. Multimodal machine learning in precision health: A scoping review. NPJ Digit Med. 2022 Nov 7;5(1):171. doi: 10.1038/s41746-022-00712-8. PubMed 36344814 ↗
  • Kim SY, Shim KN, Lee JH, Lim JY, Kim TO, Choe AR, Tae CH, Jung HK, Moon CM, Kim SE, Jung SA. Comparison of the Diagnostic Ability of Endoscopic Ultrasonography and Abdominopelvic Computed Tomography in the Diagnosis of Gastric Subepithelial Tumors. Clin Endosc. 2019 Nov;52(6):565-573. doi: 10.5946/ce.2019.019. Epub 2019 Jul 17. PubMed 31311912 ↗
  • Lefort C, Gupta V, Lisotti A, Palazzo L, Fusaroli P, Pujol B, Gincul R, Fumex F, Palazzo M, Napoleon B. Diagnosis of gastric submucosal tumors and estimation of malignant risk of GIST by endoscopic ultrasound. Comparison between B mode and contrast-harmonic mode. Dig Liver Dis. 2021 Nov;53(11):1486-1491. doi: 10.1016/j.dld.2021.06.013. Epub 2021 Jul 14. PubMed 34272196 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2026, 8 months after the start.

Of 34 observational studies under Gastrointestinal Stromal Tumors, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 90. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 22, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Jun 2026
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07078136
Responsible party
Bin Cheng (Professor, Huazhong University of Science and Technology) — Principal investigator
First posted
Jul 22, 2025
Start date
Jul 28, 2025
Primary completion
Mar 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jul 31, 2025

Study contacts

Bin Cheng
Contact
b.cheng@tjh.tjmu.edu.cn
+8613986097542

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion